TW340045B - Extended zero order release pharmaceutical composition - Google Patents
Extended zero order release pharmaceutical compositionInfo
- Publication number
- TW340045B TW340045B TW084100943A TW84100943A TW340045B TW 340045 B TW340045 B TW 340045B TW 084100943 A TW084100943 A TW 084100943A TW 84100943 A TW84100943 A TW 84100943A TW 340045 B TW340045 B TW 340045B
- Authority
- TW
- Taiwan
- Prior art keywords
- drug
- ionizable compound
- hydrogel
- pharmaceutically acceptable
- base metal
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000000017 hydrogel Substances 0.000 abstract 5
- 239000010953 base metal Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000001488 sodium phosphate Substances 0.000 abstract 2
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 150000008051 alkyl sulfates Chemical class 0.000 abstract 1
- -1 allyl methyl cellulose Chemical compound 0.000 abstract 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 abstract 1
- 229960004166 diltiazem Drugs 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 229910001510 metal chloride Inorganic materials 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000010981 methylcellulose Nutrition 0.000 abstract 1
- 229960002900 methylcellulose Drugs 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 229960001722 verapamil Drugs 0.000 abstract 1
- 239000000230 xanthan gum Substances 0.000 abstract 1
- 235000010493 xanthan gum Nutrition 0.000 abstract 1
- 229920001285 xanthan gum Polymers 0.000 abstract 1
- 229940082509 xanthan gum Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/195,377 US5419917A (en) | 1994-02-14 | 1994-02-14 | Controlled release hydrogel formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW340045B true TW340045B (en) | 1998-09-11 |
Family
ID=22721188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW084100943A TW340045B (en) | 1994-02-14 | 1995-02-07 | Extended zero order release pharmaceutical composition |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5419917A (zh) |
| EP (1) | EP0744942B1 (zh) |
| JP (1) | JPH10500658A (zh) |
| AT (1) | ATE220896T1 (zh) |
| AU (1) | AU680112B2 (zh) |
| CA (1) | CA2182587A1 (zh) |
| DE (1) | DE69527509T2 (zh) |
| NZ (1) | NZ279648A (zh) |
| TW (1) | TW340045B (zh) |
| WO (1) | WO1995021607A1 (zh) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911216B1 (en) | 1994-10-12 | 2005-06-28 | Genzyme Corporation | Targeted delivery via biodegradable polymers |
| WO1996029987A1 (en) * | 1995-03-24 | 1996-10-03 | Focal, Inc. | Reduction of adhesions using controlled delivery of active oxygen inhibitors |
| US5624677A (en) * | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US5888534A (en) * | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| WO1997026865A1 (en) * | 1996-01-29 | 1997-07-31 | Edward Mendell Co., Inc. | Sustained release excipient |
| US5830503A (en) * | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
| IN186245B (zh) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| US8679534B2 (en) * | 1997-12-12 | 2014-03-25 | Andrx Labs, Llc | HMG-CoA reductase inhibitor extended release formulation |
| US20040029962A1 (en) * | 1997-12-12 | 2004-02-12 | Chih-Ming Chen | HMG-COA reductase inhibitor extended release formulation |
| JP4221068B2 (ja) * | 1997-12-17 | 2009-02-12 | 興和創薬株式会社 | テオフィリン徐放性錠剤及びその製造方法 |
| US6090411A (en) * | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| ES2221370T3 (es) | 1998-04-03 | 2004-12-16 | Egalet A/S | Composicion de liberacion controlada. |
| US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
| US20020169145A1 (en) * | 1998-10-14 | 2002-11-14 | Rajen Shah | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| WO2000033818A1 (en) | 1998-12-11 | 2000-06-15 | Nostrum Pharmaceuticals, Inc. | Sustained release tablet containing hydrocolloid and cellulose ether |
| US20060153914A1 (en) * | 1999-12-10 | 2006-07-13 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
| US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
| US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| US20060127474A1 (en) * | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
| PT1429802E (pt) * | 2001-09-28 | 2013-01-24 | Tntgamble Inc | Sistema de entrega para componente biológico |
| US20070098784A1 (en) * | 2001-09-28 | 2007-05-03 | Nutraceutix, Inc. | Delivery system for biological component |
| CA2465405A1 (en) * | 2001-11-02 | 2003-05-08 | Wockhardt Limited | Controlled release compositions for macrolide antimicrobial agents |
| US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| PT1461017E (pt) * | 2001-11-19 | 2006-07-31 | Lupin Ltd | Composicao farmaceutica para a libertacao controlada de um antibiotico beta-lactamico |
| MXPA04006875A (es) * | 2002-01-18 | 2004-12-06 | Control Delivery Sys Inc | Sistema de gel polimerico para suministro controlado de cofarmacos. |
| AU2003275953A1 (en) * | 2002-11-08 | 2004-06-07 | Egalet A/S | Controlled release carvedilol compositions |
| PT1576138T (pt) | 2002-11-15 | 2017-05-03 | Idenix Pharmaceuticals Llc | 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae |
| ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| DE602004014747D1 (de) * | 2003-03-26 | 2008-08-14 | Egalet As | Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen |
| WO2006004774A2 (en) * | 2004-06-28 | 2006-01-12 | Stanford University | Laulimalide analogues as therapeutic agents |
| CN101188999B (zh) * | 2005-06-03 | 2012-07-18 | 尹格莱特股份有限公司 | 用于递送分散在分散介质中的活性物质的药物传递系统 |
| US8778395B2 (en) * | 2005-08-11 | 2014-07-15 | Andrx Labs, Llc | Diltiazem controlled release formulation and method of manufacture |
| US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
| US8124598B2 (en) * | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
| US20100291205A1 (en) * | 2007-01-16 | 2010-11-18 | Egalet A/S | Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| ES2574836T3 (es) * | 2007-06-08 | 2016-06-22 | Boehringer Ingelheim International Gmbh | Formulación de liberación prolongada de nevirapina |
| JP2010529142A (ja) * | 2007-06-08 | 2010-08-26 | アドレネクス・ファーマシューティカルズ，インコーポレイテッド | アドレナリン調節異常症を治療する徐放性の製剤および方法 |
| US20100172991A1 (en) * | 2007-06-08 | 2010-07-08 | Henry Joseph Horacek | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation |
| US20100160274A1 (en) * | 2007-09-07 | 2010-06-24 | Sharon Sageman | 7-KETO DHEA for Psychiatric Use |
| EP2331088A4 (en) | 2008-08-06 | 2011-10-12 | Gosforth Ct Holdings Pty Ltd | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES |
| EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| KR20150059167A (ko) | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | 제어된 방출을 위한 남용 제지 약학적 조성물 |
| US20150133516A1 (en) | 2013-11-13 | 2015-05-14 | Brian K. Adams | Methods and Compositions for Treating ADHD |
| MX373002B (es) * | 2014-03-11 | 2020-04-30 | Redhill Biopharma Ltd | Formas de dosificacion sólida de liberación extendida de ondansetrón para tratar bien sea síntomas de náusea, vómito o diarrea |
| EP3316862A4 (en) | 2015-07-02 | 2019-02-06 | University of Louisville Research Foundation, Inc. | MICROVESICLE COMPOSITIONS OBTAINED FROM EDIBLE PLANTS FOR THE DISTRIBUTION OF MIRNA AND METHOD FOR THE TREATMENT OF CANCER |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4220153A (en) * | 1978-05-08 | 1980-09-02 | Pfizer Inc. | Controlled release delivery system |
| US4220152A (en) * | 1978-05-08 | 1980-09-02 | Pfizer Inc. | Delivery system |
| US4361545A (en) * | 1979-05-21 | 1982-11-30 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion |
| US4264573A (en) * | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US5082668A (en) * | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
| US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4894233A (en) * | 1984-10-05 | 1990-01-16 | Sharma Shri C | Novel drug delivery system for decongestants |
| US4657757A (en) * | 1985-03-29 | 1987-04-14 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
| US4695591A (en) * | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
| US4601894A (en) * | 1985-03-29 | 1986-07-22 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
| US4666705A (en) * | 1985-06-03 | 1987-05-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| FR2585246A1 (fr) * | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
| US5073380A (en) * | 1987-07-27 | 1991-12-17 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4946686A (en) * | 1987-09-24 | 1990-08-07 | Merck & Co., Inc. | Solubility modulated drug delivery system |
| IE60311B1 (en) * | 1987-09-24 | 1994-06-29 | American Home Prod | Sustained release etodolac |
| US4996061A (en) * | 1987-10-07 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
| US4994273A (en) * | 1987-11-02 | 1991-02-19 | Merck & Co., Inc. | Solubility modulated drug delivery device |
| US4999226A (en) * | 1988-06-01 | 1991-03-12 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination |
| US5085865A (en) * | 1989-04-12 | 1992-02-04 | Warner-Lambert Company | Sustained release pharmaceutical preparations containing an analgesic and a decongestant |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5000962A (en) * | 1989-08-25 | 1991-03-19 | Schering Corporation | Long acting diltiazem formulation |
| US4992277A (en) * | 1989-08-25 | 1991-02-12 | Schering Corporation | Immediate release diltiazem formulation |
| DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| EP0484106A1 (en) * | 1990-11-01 | 1992-05-06 | Merck & Co. Inc. | Controlled release formulations |
| JPH04316515A (ja) * | 1991-04-12 | 1992-11-06 | Shin Etsu Chem Co Ltd | 徐放性錠剤 |
| US5252338A (en) * | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
| US5190765A (en) * | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
-
1994
- 1994-02-14 US US08/195,377 patent/US5419917A/en not_active Expired - Lifetime
-
1995
- 1995-01-18 NZ NZ279648A patent/NZ279648A/en unknown
- 1995-01-18 AU AU16836/95A patent/AU680112B2/en not_active Ceased
- 1995-01-18 AT AT95908570T patent/ATE220896T1/de active
- 1995-01-18 WO PCT/US1995/000717 patent/WO1995021607A1/en not_active Ceased
- 1995-01-18 JP JP7521221A patent/JPH10500658A/ja active Pending
- 1995-01-18 CA CA002182587A patent/CA2182587A1/en not_active Abandoned
- 1995-01-18 DE DE69527509T patent/DE69527509T2/de not_active Expired - Fee Related
- 1995-01-18 EP EP95908570A patent/EP0744942B1/en not_active Revoked
- 1995-02-07 TW TW084100943A patent/TW340045B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0744942A1 (en) | 1996-12-04 |
| NZ279648A (en) | 1997-06-24 |
| EP0744942A4 (en) | 1997-11-12 |
| US5419917A (en) | 1995-05-30 |
| WO1995021607A1 (en) | 1995-08-17 |
| JPH10500658A (ja) | 1998-01-20 |
| EP0744942B1 (en) | 2002-07-24 |
| DE69527509T2 (de) | 2003-02-27 |
| DE69527509D1 (de) | 2002-08-29 |
| ATE220896T1 (de) | 2002-08-15 |
| AU680112B2 (en) | 1997-07-17 |
| CA2182587A1 (en) | 1995-08-17 |
| AU1683695A (en) | 1995-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW340045B (en) | Extended zero order release pharmaceutical composition | |
| EP1137403A4 (en) | A HYDROCOLLOID AND A DELIVERY-RELATED TABLET CONTAINING CELLULOSE ETHER | |
| NZ295211A (en) | Topical aqueous gel containing a water-soluble cellulose derivative, propylene glycol & drug(s) for haemorrhoids | |
| NZ510487A (en) | Pharmaceutical composition comprising ciprofloxacin, sodium alginate, xanthan gum and a cross-linker polymer in a tablet or capsule form | |
| BR0003158A (pt) | Formulação de dosagem oral de derretimentoinstantâneo | |
| IL111647A0 (en) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them | |
| UA26455C2 (uk) | Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта | |
| HK95590A (en) | Controlled release naproxen and naproxen sodium tablets | |
| ES2190075T3 (es) | Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico. | |
| IL114193A0 (en) | Ophthalmic pharmaceutical compositions | |
| BR9810984A (pt) | Composto de triazol, uso do mesmo, e, composição farmacêutica | |
| KR890004686A (ko) | 서방성 에토돌락 | |
| MY126625A (en) | Compositions containing diphosphonic acids | |
| EA200600884A1 (ru) | Композиции комплексов экстроген-циклодекстрин | |
| CO4700482A1 (es) | Formulaciones de un analogo monomero de insulina | |
| BR9815861A (pt) | Composição farmacêutica com revestimento entérico e método de fabricação | |
| BG66095B1 (bg) | Хидрофилен състав с контролирано освобождаване съдържащ прежелатинирано нишесте в препарат | |
| AU6136199A (en) | Dosage form comprising therapeutic formulation | |
| CA2392545A1 (en) | Pharmaceutical formulations for thyroid hormones | |
| KR920003971A (ko) | 점안액 조성물 | |
| IL143375A0 (en) | Sustained release matrix systems for highly soluble drugs | |
| NZ514129A (en) | Tolperison-containing, pharmaceutical preparation for oral administration | |
| JP2002524415A5 (zh) | ||
| CA2157323A1 (en) | Gepirone dosage form | |
| RU2002123182A (ru) | Содержащая ибупрофен композиция |